The Global Artificial Blood Market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2021-2028). The research presents a complete assessment of the market and contains Future trend, Current Growth Factors, attentive opinions, facts, historical data, and statistically supported and industry validated market data.
Artificial Blood Market report presents the detail analysis of the parent market based on elite players, present, past and futuristic data which will serve as a profitable guide for all the industry competitors. Key players in the Artificial Blood market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All measurement shares, splits, and breakdowns have been resolute using secondary sources and verified primary sources. The Artificial Blood Market report begins with a basic overview of the industry lifecycle, definitions, classifications, applications, and industry chain structure and all these together will help leading players understand scope of the Market, what characteristics it offers and how it will fulfill customer’s requirements.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/11
Artificial blood is a product made to act as a substitute for red blood cells. Although true blood serves a lot different purposes in the body, artificial blood’s sole purpose is to transport oxygen and carbon dioxide throughout the body. For decades, scientists have been trying to develop artificial blood from various sources and through different methods to address the shortage of blood for transfusions. Inadequate number of blood donors and the criticality of blood-type rejection have encouraged researchers to develop artificial blood, thus reducing the dependency on blood donors.
Transfusion of red blood cells (RBCs) is a standard and indispensable therapy for anemic conditions. There has been extensive development in the process of blood transfusion including development of acid-citrate-dextrose blood preservation solution and cloning of ABO gene. However, blood transfusion comes with a high risk of infections. Recombinant erythropoietin stimulating agent therapy has been the prominent therapy in cases such as chronic kidney disease, and chronic anemic conditions. Yet in thrombotic and neoplastic complications, blood transfusion is the only option. Hence, RBC production from hematopoietic stem cells has been the focus of regenerative therapy, with major players investing billions of dollars in R&D related to this technique. However, the final product is yet to receive U.S. Food & Drug Administration (FDA) approval.
Global Artificial Blood Market Development
There has been significant progress in the global artificial blood market with respect to finding a suitable method to produce blood cells. Scientists have been trying to develop artificial blood from diverse molecules ranging from perfluorocarbons to hemoglobin. With the advent of research in stem cells, researchers began to develop RBCs from stem cells of cord blood. In 2009, the enrollment for the first clinical trials of stem-cell based red blood cells started. This study used stem cells from cord blood and adult bone marrow. The study was conducted at the Hematological Laboratory at the University of Paris VI.
Purchase This Premium Report Here To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/11
A similar research conducted by scientists at the University of Bristol and the UK’s National Health Service (NHS) using stem cells from adult and umbilical cord blood has shown successful results from initial studies. The study is scheduled to enter clinical trials with 20 subjects in 2017. The focus of these trials is to provide special treatment for specific patient groups, rather than act as complete replacement for blood.
Artificial Blood Market Potential
According to the World Health Organization (WHO), there are around 50,000 stem cell transplantations performed annually worldwide, which include 2,000 cord blood hematopoietic stem cell transplants performed each year. Since stem cells from cord blood do not require perfect human leukocyte antigen (HLA) tissue matching, its use has been increased and can be used allogenically. Moreover, it has less incidence of graft v/s host disease. According to the New York Blood Center (NYBC), which is the largest cord blood bank globally in terms of units stored, over half of all stem cell transplants in children, in the U.S., use cord blood. In Japan, A similar statistic has been noted among adults.
Post the trial in 2017, production is expected to start in the following 8 to 10 years, thus prolonging the commercialization of product in the global artificial blood market.
Global Artificial Blood Market Future Outlook
Cord blood stem cell transplantation has proved to be a successful therapy in treatment of around 70 diseases. Developing artificial blood can be of great aid to meet the demand-supply gap in blood transfusion, more so considering the fact that finding compatible donors for sickle cell anemia and thalassemia patients is a mammoth task. Development of artificial blood could be the most viable solution to address the unmet needs among these patients. Continued investment in research and development is crucial for ensuring the commercial application of this technology, a very critical factor to contribute towards development of artificial blood market. Being a critical therapy for a severe life condition, the artificial blood market is expected to get a product in a decade or so.
Key players in the global artificial blood market are focused on research and development activities to expand their product portfolio. For instance, in May 2019, Baxter International started a new research on 3-in-1 Oxiris filter Set for continuous renal replacement therapy (CRRT) and sepsis management. The filter removes cytokines and endotoxins from the blood.
Major companies are also focused on conducting clinical trials to assess the efficacy of blood systems. For instance, in June 2018, Cerus Corporation presented its European Phase 3 study that evaluated the efficacy and safety of INTERCEPT-treated red blood cells (RBCs) in thalassemia major patients, at the 23rd Congress of European Hematology Association (EHA) in Stockholm, Sweden.
Moreover, in December 2018, Cerus Corporation announced the initiation and first patient enrollment in a Phase III study to evaluate the efficacy and safety of the INTERCEPT Blood System for red blood cells in patients undergoing complex cardiac surgery procedures.
Get Sample Report with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-sample/11
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027